A long-term, open-label study of valbenazine for tardive dyskinesia / Jean-Pierre Lindenmayer en CNS Spectrums, Año 2021 Vol. 26 - No. 4 (Agosto) 

Público ISBD [artículo]  inCNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353 Título : A long-term, open-label study of valbenazine for tardive dyskinesia Tipo de documento: texto impreso Autores: Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor Fecha de publicación: 2022 Artículo en la página: pp. 345 - 353 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo Resumen: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Link: ./index.php?lvl=notice_display&id=28341 [artículo] A long-term, open-label study of valbenazine for tardive dyskinesia [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Cherian Verghese, Autor ; Stephen R. Marder, Autor . - 2022 . - pp. 345 - 353. Idioma : Inglés (eng) Idioma original : Inglés (eng) in CNS Spectrums > Año 2021 Vol. 26 - No. 4 (Agosto) . - pp. 345 - 353 Palabras clave: Discinesia tardía, Valbenazina, Inhibidor de VMAT2, Antipsicóticos, Esquizofrenia, Trastorno del estado de ánimo Resumen: Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Link: ./index.php?lvl=notice_display&id=28341

---

1 (1 - 1 / 1)